DEVELOPMENT OF LEVODOPA LOADED ALBUMIN NANOPARTICLES FOR NOSE-TO-BRAIN DELIVERY
Keywords:
Levodopa; albumin nanoparticles; nose-to-brain delivery; intranasal administration; Parkinson’s disease; nanotechnology; drug encapsulation; brain targeting.Abstract
Parkinson’s disease is a progressive neurodegenerative disorder characterized by the degeneration of dopaminergic neurons and a reduction in dopamine levels in the brain. Levodopa (L-DOPA) remains a principal pharmacological agent for the management of motor symptoms associated with Parkinson’s disease. However, its therapeutic performance may be limited by peripheral metabolism, variable systemic exposure, and challenges associated with delivering sufficient drug concentrations to the central nervous system. Intranasal administration has attracted considerable interest as a potential route for nose-to-brain drug delivery.
References
1.Design and Development of Levodopa Loaded Polymeric Nanoparticles for Intranasal Delivery. Pharmaceuticals. 2022;15(3):370. https://doi.org/10.3390/ph15030370
2.Formica ML, Real DA, Picchio ML, Catlin E, Donnelly RF, Paredes AJ. On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles. Applied Materials Today. 2022;29:101631. https://doi.org/10.1016/j.apmt.2022.101631
3.Drath I, Richter F, Feja M. Nose-to-brain drug delivery: from bench to bedside. Translational Neurodegeneration. 2025;14:23. https://doi.org/10.1186/s40035-025-00481-w
4.In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery. International Journal of Pharmaceutics. 2020. https://pubmed.ncbi.nlm.nih.gov/32141798/
5.Nanocarriers-Assisted Nose-to-Brain Delivery of Levodopa: Current Progress and Prospects. Applied Sciences. 2025;15(1):331. https://doi.org/10.3390/app15010331